<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04638478</url>
  </required_header>
  <id_info>
    <org_study_id>PRECODE-MRI</org_study_id>
    <nct_id>NCT04638478</nct_id>
  </id_info>
  <brief_title>PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI</brief_title>
  <official_title>PREselection of Patients at Risk for COgnitive DEcline After Radiotherapy Using Advanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meningioma are slow growing and frequently occurring intracranial tumors, responsible for 33%&#xD;
      of all asymptomatic intracranial tumors and 13-26% of all symptomatic primary brain tumors.&#xD;
      The 10-year survival rate is 72%. A variety of treatment options is available for symptomatic&#xD;
      meningioma including surgical removal with or without radiotherapy or radiotherapy alone.&#xD;
      These therapies can have negative impact on cerebral functioning.&#xD;
&#xD;
      After high dose radiotherapy for primary or metastatic brain tumors 50-90% of &gt; 6 months'&#xD;
      survivors develop irreversible disabling cognitive decline leading to premature loss of&#xD;
      independence, reduced Quality of Life (QOL) as well as significant economic burden both at&#xD;
      the individual as societal level. Especially for patients with a good prognosis like benign&#xD;
      meningioma, maintaining neurocognitive function is crucial. Understanding the mechanisms&#xD;
      underlying radiation induced cognitive decline is complex and which brain areas to spare are&#xD;
      an important subject of research.&#xD;
&#xD;
      Evaluation methods to assess cognitive function and predict cognitive decline are urgently&#xD;
      needed, this will allow the development of optimized treatment strategies with the aim to&#xD;
      preserve or even improve cognitive function in meningioma patients. Improvements in the field&#xD;
      of neuroimaging techniques (i.e. advanced MRI techniques) have the possibility to identify&#xD;
      areas susceptible to cognitive impairment. This allows in the future a more personalized&#xD;
      radiation treatment by identifying patients at risk, by optimizing the radiotherapy dose to&#xD;
      specific brain regions, that could eventually reduce or prevent, cognitive decline.&#xD;
      Improvements in the field of radiotherapy for example by higher precision treatment such&#xD;
      proton therapy have potential in obtaining these more individualized strategies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">April 8, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation cognitive failure and radiotherapy dose</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>Correlation between the delta cognitive failure score (baseline vs 2 years) and radiotherapy dose in cognition related brain regions (supratentorial brain, hippocampus left/right and anterior/posterior, cerebellum anterior/posterior).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation baseline imaging and patient specific parameters</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>Correlation between baseline imaging (advanced MRI sequence) and patient specific parameters (e.g. baseline cognitive status, age, Karnofsky index (KPS), co-morbidity, alcohol consumption, smoking, medication)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RT induced cognitive change measured with extensive cognitive testing</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>RT-induced cognitive change measured with extensive cognitive testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation advanced MRI and PROMS</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>Correlation of advanced MRI and treatment/dose parameters to PROMS; EQ/5D, QLQ/C30, QLQ/BN20, Cognitive Failure questionnaire (CFQ) , Multidimentional Fatigue Index (MVI/20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation susceptibility of organs by Normal Tissue Complication Probability (NTCP)</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>Identification of radiation susceptibility of individual anatomical and functional central nervous system (CNS) organs (e.g. (hippocampi, frontal lobe, cerebellum, brain) for radiation damage by relating dose-volume histogram of the organs with information with neurocognitive test results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity neurocognitive tests</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>Sensitivity of additional extensive neurocognitive tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation advanced MRI and radiotherapy modality</measure>
    <time_frame>2 years after radiotherapy</time_frame>
    <description>Correlation of advanced MRI and treatment/dose parameters and radiotherapy modality (photon vs proton)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">67</enrollment>
  <condition>Meningioma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRECODE-MRI</intervention_name>
    <description>Patients with meningioma WHO I tumours treated with radiotherapy will be included, undergoing extensive cognitive testing combined with advanced brain MRI scans just before, 3 and 24 months after radiotherapy</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult (18 years or older) patients with meningioma tumours (WHO I) in a good clinical&#xD;
        condition treated with curative intend using radiotherapy (proton or photon) without other&#xD;
        known malignancies.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meningioma WHO I, grading based on pathology or radiological features&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Karnofsky Performance Score 70 or above.&#xD;
&#xD;
          -  Ability to comply with the protocol, including neuropsychological testing and imaging.&#xD;
&#xD;
          -  Ability to understand the requirements of the study and to give written informed&#xD;
             consent, as determined by the treating physician.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resection meningioma &lt; 3mnd&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any prior cranial radiotherapy&#xD;
&#xD;
          -  Any prior chemotherapy&#xD;
&#xD;
          -  Contra-indication for MR imaging (i.e. metal implants, claustrophobia)&#xD;
&#xD;
          -  Any other serious medical condition that could interfere with follow-up.&#xD;
&#xD;
          -  Severe aphasia or language barrier interfering with assessing endpoints (i.e.&#xD;
             completion of questionnaires or neurocognitive performance)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Zegers</last_name>
    <role>Study Chair</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Eekers</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Zegers</last_name>
    <phone>+31884455600</phone>
    <email>karen.zegers@maastro.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Danielle Eekers</last_name>
    <phone>+31884455600</phone>
    <email>danielle.eekers@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Zegers</last_name>
      <phone>+31884455600</phone>
      <email>karen.zegers@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Danielle Eekers</last_name>
      <phone>+31884455600</phone>
      <email>danielle.eekers@maastro.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningioma</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>MRI</keyword>
  <keyword>Neurocognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

